8-K: Incannex Healthcare Completes Dosing in Bioavailability Trial for Sleep Apnea Drug IHL-42X

Incannex Healthcare has completed dosing in a 115-participant bioavailability/bioequivalence clinical trial for its sleep apnea drug candidate, IHL-42X, with no serious adverse events reported.

Summary

• Incannex Healthcare has finished dosing all 115 participants in its bioavailability/bioequivalence (BA/BE) clinical trial for IHL-42X, a drug targeting obstructive sleep apnea (OSA).
• The trial compared the bioavailability of dronabinol and acetazolamide in IHL-42X to the reference drugs Marinol and Taro acetazolamide.
• The study also assessed the impact of food on the bioavailability of IHL-42X.
• Each participant completed four treatment periods, receiving single doses of IHL-42X, Marinol, or acetazolamide under fasted conditions, and IHL-42X under fed conditions.
• Blood samples were collected to analyze levels of acetazolamide, THC, and THC metabolites.
• No serious adverse events were reported during the study.
• Data analysis will be conducted over the coming months to determine the pharmacokinetics of IHL-42X compared to the reference drugs.
• This data will support future regulatory submissions by allowing Incannex to rely on existing safety and toxicology data for the reference drugs.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the successful completion of dosing in the clinical trial and the absence of serious adverse events. The company is progressing towards regulatory approval for a drug that addresses a significant unmet medical need.

Positives

• The completion of dosing in the BA/BE study is a significant milestone for the IHL-42X research program.
• The large number of participants in the study will provide valuable pharmacokinetic data.
• The ability to rely on existing safety and toxicology data for reference drugs reduces the burden on Incannex.
• The Phase 2/3 RePOSA clinical trial is ongoing after dosing commenced in May 2024.
• A previous Phase 2 trial showed IHL-42X reduced the average apnoea-hypopnoea index (AHI) by 50.7% versus baseline.

Risks

• The company is still in the clinical trial phase, and there is no guarantee of regulatory approval for IHL-42X.
• The analysis of the data from the BA/BE study is still ongoing, and the results could impact the future development of IHL-42X.
• The company is reliant on the success of its clinical trials to achieve commercial success.

Future Outlook

Incannex will continue to analyze the data from the BA/BE study and progress the Phase 2/3 RePOSA clinical trial for IHL-42X. The company anticipates greatly improved treatment compliance and outcomes from a pharmaceutical product, such as IHL-42X, subject to further clinical assessment and approval from regulators.

Management Comments

• Incannex Chief Scientific Officer Dr Mark Bleackley said 'Completion of dosing in the BA/BE study is an important milestone in the IHL-42X research program.'
• Dr. Bleackley also stated that the pharmacokinetic data from the study will be 'incredibly valuable' for the continued development of IHL-42X.
• Dr. Bleackley noted that the ability to rely on safety and toxicology data for the reference listed drugs reduces the burden on Incannex.

Industry Context

The announcement is significant as it addresses the unmet need for pharmaceutical treatments for obstructive sleep apnea, a condition currently managed primarily with CPAP machines. The global market for sleep apnea detection and treatment is approximately US$10 billion per annum and growing. Incannex is positioning itself to capture a portion of this market with IHL-42X.

Comparison to Industry Standards

• The study design, comparing IHL-42X to FDA-approved reference drugs like Marinol and Taro acetazolamide, is a standard approach for demonstrating bioequivalence.
• The use of a fixed-dose combination drug is a common strategy in pharmaceutical development to improve patient compliance and efficacy.
• The focus on pharmacokinetic data is crucial for regulatory approval and is consistent with industry best practices.
• The company's previous Phase 2 trial results showing a 50.7% reduction in AHI are promising compared to the limitations of current treatments like CPAP.

Stakeholder Impact

• Shareholders may view this as positive progress in the development of IHL-42X.
• Patients with obstructive sleep apnea may benefit from a new pharmaceutical treatment option.
• The company's employees are involved in the clinical trial process and the development of IHL-42X.

Next Steps

• Incannex will analyze the data collected from the BA/BE study.
• The company will continue the Phase 2/3 RePOSA clinical trial.
• Incannex will use the data to support future regulatory submissions for IHL-42X.

Key Dates

Keywords

IHL-42X, obstructive sleep apnea, bioavailability, clinical trial, dronabinol, acetazolamide, pharmacokinetics, FDA, cannabinoid, sleep apnea